

Pharmaids Pharmaceuticals Limited.

4-4-211/212/11-12, Inderbagh, Hyderabad – 500 095.

Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 31ST DECEMBER 2014

PART - I

(Rs. in Lakhs)

S. No	Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
		Un-audited					Audited
1	Income from Operations						
	(a) Net Sales/Income from operations	50.61	45.29	28.38	141.10	44.58	140.52
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations	50.61	45.29	28.38	141.10	44.58	140.52
2	Expenses						
	a. Consumption of raw materials	3.02	1.55	1.92	7.49	0.97	0.00
	b. Purchases of stock-in-trade	39.37	25.14	18.72	85.76	29.93	103.94
	c. Increase/decrease in stock in trade and WIP	(15.00)	3.03	(1.32)	(14.06)	(1.90)	(5.52)
	d. Power & Fuel	0.00	0.00	0.00	0.00	0.00	0.00
	e. Sales Tax and other Taxes	0.00	0.00	0.00	0.00	0.00	0.00
	f. Employees Cost	5.65	4.87	2.54	14.95	3.34	9.55
	g. Depreciation	1.68	1.68	2.00	5.04	2.00	8.00
	h. Other expenditure	14.09	11.65	4.53	48.55	20.59	76.18
	Total	48.81	47.92	28.39	147.73	54.93	192.15
	(Any item exceeding 10% of the total expenditure to be shown separately)	0.00	0.00	0.00	0.00	0.00	0.00
3	Profit / (Loss) from Operations before other income, finance costs and Exceptional Items (1-2)	1.80	(2.63)	(0.01)	(6.63)	(10.35)	(51.63)
4	Other Income	0.04	4.95	3.03	12.42	0.95	15.84
5	Profit / (Loss) from Ordinary activities before finance costs and exceptional items	1.84	2.32	3.02	5.79	(9.40)	(35.79)
6	Finance Cost	0.00	0.00	0.17	0.00	0.17	0.81
7	Profit / (Loss) from Ordinary activities after finance costs but before exceptional items	1.84	2.32	2.85	5.79	(9.57)	(36.60)
8	Exceptional Items - Expenditure / (Income)	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary Activities	1.84	2.32	2.85	5.79	(9.57)	(36.60)
10	Tax expense						
	a) Provision for Taxation	0.00	0.00	0.00	0.00	0.00	0.00
	b) Provision for Deferred tax	0.00	0.00	0.00	0.00	0.00	(1.17)
	c) MAT Credit	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit (+)/ Loss (-) from ordinary activities after tax	1.84	2.32	2.85	5.78	(9.57)	(35.43)
12	Extraordinary items (net of tax expense Rs Nil)	Nil	Nil	Nil	Nil	Nil	Nil
13	Net Profit (+)/Loss (-) for the period	1.84	2.32	2.85	5.78	(9.57)	(35.43)
14	Paid-up equity share capital (Face value of the Share is Rs 10/- each)	336.31	336.31	336.31	336.31	336.31	336.31
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	9.94	9.94	9.94	9.94	9.94	9.94
16	Earnings Per Share (before extraordinary items - not annualised)						
	a) Basic	0.05	0.07	0.08	0.17	-0.28	(1.04)
	b) Diluted	0.05	0.07	0.08	0.17	-0.28	(1.04)



[illegible]

Date :

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of un-audited standalone financial results of **PHARMAIDS PHARMACEUTICALS LIMITED** ("the Company") for the quarter ended 31st December, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter Group Shareholding' which has been traced from disclosures made by the management and has not been audited by us. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an opinion. We have not performed an audit and accordingly we do not express such an opinion.

Management has informed to us being quarterly closing, the company has not accounted for taxes on income as required under AS-22 i.e. Deferred Tax and Income Tax, the same will be considered at the time of year end. Attention is drawn towards Note no.5 relating to accounting of Depreciation as per Schedule II to the Companies Act, 2013.

Based on our review conducted as above and subject to the points mentioned above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the Accounting Standards issued under the Companies (Accounting Standards) Rules, 2006 which continue to apply as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting policies and practices generally accepted in India has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchange including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **RAKESH S JAIN & ASSOCIATES**
Chartered Accountants
Firm Reg No. 010129S



(B. RAMESH KUMAR)
Partner
M. No. 200304

Date: 14.02.2015
Place: Hyderabad.